6.
Vesikari T, Karvonen A, Ferrante S, Ciarlet M
. Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study. Eur J Pediatr. 2010; 169(11):1379-86.
PMC: 2943584.
DOI: 10.1007/s00431-010-1242-3.
View
7.
Ali S, Kazi A, Cortese M, Fleming J, Parashar U, Jiang B
. Impact of different dosing schedules on the immunogenicity of the human rotavirus vaccine in infants in Pakistan: a randomized trial. J Infect Dis. 2014; 210(11):1772-9.
DOI: 10.1093/infdis/jiu335.
View
8.
Southern J, Andrews N, Sandu P, Sheppard C, Waight P, Fry N
. Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England. PLoS One. 2018; 13(5):e0195799.
PMC: 5969732.
DOI: 10.1371/journal.pone.0195799.
View
9.
Sampath A, Padmanabhan R
. Molecular targets for flavivirus drug discovery. Antiviral Res. 2008; 81(1):6-15.
PMC: 2647018.
DOI: 10.1016/j.antiviral.2008.08.004.
View
10.
Lewandowsky S, Ecker U, Seifert C, Schwarz N, Cook J
. Misinformation and Its Correction: Continued Influence and Successful Debiasing. Psychol Sci Public Interest. 2015; 13(3):106-31.
DOI: 10.1177/1529100612451018.
View
11.
Yugi K, Kubota H, Hatano A, Kuroda S
. Trans-Omics: How To Reconstruct Biochemical Networks Across Multiple 'Omic' Layers. Trends Biotechnol. 2016; 34(4):276-290.
DOI: 10.1016/j.tibtech.2015.12.013.
View
12.
Waight P, Andrews N, Ladhani S, Sheppard C, Slack M, Miller E
. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015; 15(5):535-43.
DOI: 10.1016/S1473-3099(15)70044-7.
View
13.
Barral-Arca R, Pardo-Seco J, Martinon-Torres F, Salas A
. A 2-transcript host cell signature distinguishes viral from bacterial diarrhea and it is influenced by the severity of symptoms. Sci Rep. 2018; 8(1):8043.
PMC: 5966427.
DOI: 10.1038/s41598-018-26239-1.
View
14.
Lucidarme J, Scott K, Ure R, Smith A, Lindsay D, Stenmark B
. An international invasive meningococcal disease outbreak due to a novel and rapidly expanding serogroup W strain, Scotland and Sweden, July to August 2015. Euro Surveill. 2016; 21(45).
PMC: 5144941.
DOI: 10.2807/1560-7917.ES.2016.21.45.30395.
View
15.
Rappuoli R, Mandl C, Black S, De Gregorio E
. Vaccines for the twenty-first century society. Nat Rev Immunol. 2011; 11(12):865-72.
PMC: 7098427.
DOI: 10.1038/nri3085.
View
16.
Best S
. The Many Faces of the Flavivirus NS5 Protein in Antagonism of Type I Interferon Signaling. J Virol. 2016; 91(3).
PMC: 5244349.
DOI: 10.1128/JVI.01970-16.
View
17.
Britton P, Dale R, Nissen M, Crawford N, Elliott E, Macartney K
. Parechovirus Encephalitis and Neurodevelopmental Outcomes. Pediatrics. 2016; 137(2):e20152848.
DOI: 10.1542/peds.2015-2848.
View
18.
Wohlbold T, Nachbagauer R, Margine I, Tan G, Hirsh A, Krammer F
. Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses. Vaccine. 2015; 33(29):3314-21.
PMC: 4472732.
DOI: 10.1016/j.vaccine.2015.05.038.
View
19.
Pollard A, Finn A, Curtis N
. Non-specific effects of vaccines: plausible and potentially important, but implications uncertain. Arch Dis Child. 2017; 102(11):1077-1081.
DOI: 10.1136/archdischild-2015-310282.
View
20.
Gomez-Rial J, Sanchez-Batan S, Rivero-Calle I, Pardo-Seco J, Martinon-Martinez J, Salas A
. Further considerations on rotavirus vaccination and seizure-related hospitalization rates. Infect Drug Resist. 2019; 12:989-991.
PMC: 6503302.
DOI: 10.2147/IDR.S208756.
View